Free Trial

MannKind (MNKD) Competitors

$4.78
-0.04 (-0.83%)
(As of 05/24/2024 ET)

MNKD vs. DVAX, IRWD, LGND, INVA, OPK, PAHC, ANAB, RDUS, LXRX, and GERN

Should you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Dynavax Technologies (DVAX), Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), Innoviva (INVA), OPKO Health (OPK), Phibro Animal Health (PAHC), AnaptysBio (ANAB), Radius Recycling (RDUS), Lexicon Pharmaceuticals (LXRX), and Geron (GERN).

MannKind vs.

MannKind (NASDAQ:MNKD) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, community ranking, earnings and analyst recommendations.

Dynavax Technologies has a net margin of 3.91% compared to MannKind's net margin of 3.78%. Dynavax Technologies' return on equity of 1.52% beat MannKind's return on equity.

Company Net Margins Return on Equity Return on Assets
MannKind3.78% -3.35% 2.08%
Dynavax Technologies 3.91%1.52%0.95%

MannKind received 106 more outperform votes than Dynavax Technologies when rated by MarketBeat users. However, 65.87% of users gave Dynavax Technologies an outperform vote while only 59.87% of users gave MannKind an outperform vote.

CompanyUnderperformOutperform
MannKindOutperform Votes
573
59.87%
Underperform Votes
384
40.13%
Dynavax TechnologiesOutperform Votes
467
65.87%
Underperform Votes
242
34.13%

49.6% of MannKind shares are held by institutional investors. Comparatively, 97.0% of Dynavax Technologies shares are held by institutional investors. 3.0% of MannKind shares are held by insiders. Comparatively, 3.0% of Dynavax Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dynavax Technologies has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MannKind$198.96M6.54-$11.94M$0.03159.39
Dynavax Technologies$232.28M6.42-$6.39M$0.06189.83

In the previous week, Dynavax Technologies had 2 more articles in the media than MannKind. MarketBeat recorded 7 mentions for Dynavax Technologies and 5 mentions for MannKind. Dynavax Technologies' average media sentiment score of 0.91 beat MannKind's score of 0.41 indicating that Dynavax Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MannKind
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Dynavax Technologies
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MannKind currently has a consensus price target of $8.00, indicating a potential upside of 67.36%. Dynavax Technologies has a consensus price target of $25.33, indicating a potential upside of 122.42%. Given Dynavax Technologies' higher probable upside, analysts plainly believe Dynavax Technologies is more favorable than MannKind.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MannKind
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Dynavax Technologies
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

MannKind has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.

Summary

Dynavax Technologies beats MannKind on 11 of the 17 factors compared between the two stocks.

Get MannKind News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MNKD vs. The Competition

MetricMannKindPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.30B$6.82B$5.15B$8.05B
Dividend YieldN/A2.76%2.84%3.96%
P/E Ratio159.3910.62104.6814.77
Price / Sales6.54247.712,486.1071.53
Price / CashN/A32.8735.8631.15
Price / Book-5.695.705.364.56
Net Income-$11.94M$139.51M$106.43M$214.00M
7 Day Performance4.14%-2.41%-1.26%-1.04%
1 Month Performance14.35%2.29%3.25%3.85%
1 Year Performance5.05%-3.90%5.13%8.64%

MannKind Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DVAX
Dynavax Technologies
4.1887 of 5 stars
$11.46
+0.6%
$25.33
+121.1%
+1.3%$1.50B$232.28M191.00408
IRWD
Ironwood Pharmaceuticals
4.3792 of 5 stars
$6.78
+5.6%
$18.40
+171.4%
-45.0%$1.06B$442.73M-1.00267Analyst Revision
News Coverage
LGND
Ligand Pharmaceuticals
4.845 of 5 stars
$87.00
+0.4%
$116.33
+33.7%
+15.8%$1.57B$131.31M16.8358Positive News
INVA
Innoviva
1.4225 of 5 stars
$16.15
+0.1%
N/A+19.2%$1.01B$310.46M7.27112Positive News
OPK
OPKO Health
4.4251 of 5 stars
$1.30
-1.5%
$3.17
+143.6%
-8.7%$906.09M$863.50M-3.713,930Analyst Upgrade
Insider Buying
News Coverage
Positive News
Gap Up
PAHC
Phibro Animal Health
4.0857 of 5 stars
$18.37
+0.8%
$14.75
-19.7%
+42.0%$743.99M$977.90M57.411,920Analyst Revision
ANAB
AnaptysBio
2.0851 of 5 stars
$23.95
-4.2%
$46.38
+93.6%
+26.3%$654.31M$17.16M-3.90117
RDUS
Radius Recycling
2.4315 of 5 stars
$18.04
-0.6%
N/A-39.3%$504.76M$2.88B-7.913,353
LXRX
Lexicon Pharmaceuticals
1.7145 of 5 stars
$1.67
-5.6%
$5.00
+199.4%
-46.4%$411.22M$1.20M-2.01285Positive News
GERN
Geron
3.837 of 5 stars
$3.70
-0.8%
$6.10
+64.9%
+10.8%$2.19B$240,000.00-10.57141Positive News

Related Companies and Tools

This page (NASDAQ:MNKD) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners